Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24989576 | 0.90 | MAPT (0.55) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL6363304 | 0.85 | MEN1 (0.65) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL22411451 | 0.85 | MAPT (0.61) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL2119288 | 0.85 | GPR119 (0.60) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL594965 | 0.84 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL31328829 | 0.84 | GPR119 (0.59) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL29426702 | 0.84 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL22388849 | 0.84 | GPR119 (0.62) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL1393764 | 0.84 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL31329004 | 0.84 | GPR119 (0.59) | MAPTALDH1A1LMNAGPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004100-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| WO-2013090497-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1423391-B8 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1423391-B1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | MAPT 2976/4885ALDH1A1 2931/4885LMNA 4184/4885 |
| US-20150004100-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | MAPT, NAT1, APP | MAPT 1/4885ALDH1A1 738/4885LMNA 437/4885 |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | CTSK, CTSS, CTSZ | MAPT 2976/4885ALDH1A1 2931/4885LMNA 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.